Literature DB >> 10579259

Beneficial effects of helium:oxygen versus air:oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease.

P Jolliet1, D Tassaux, J M Thouret, J C Chevrolet.   

Abstract

OBJECTIVE: To test the hypothesis that, in decompensated chronic obstructive pulmonary disease (COPD), noninvasive pressure support ventilation using 70:30 helium:oxygen instead of 70:30 air:oxygen could reduce dyspnea and improve ventilatory variables, gas exchange, and hemodynamic tolerance.
DESIGN: Prospective, randomized, crossover study.
SETTING: Medical intensive care unit, university tertiary care center. PATIENTS: Nineteen patients with severe COPD (forced 1-sec expiratory volume of 0.83+/-0.3 l) hospitalized in the intensive care unit for noninvasive pressure support ventilation after initial stabilization with noninvasive pressure support for no more than 24 hrs after intensive care unit admission.
INTERVENTIONS: Noninvasive pressure support ventilation was administered in the following randomized crossover design: a) 45 min with air:oxygen or helium:oxygen; b) no ventilation for 45 min; and c) 45 min with air:oxygen or helium:oxygen.
MEASUREMENTS AND MAIN RESULTS: Air:oxygen and helium:oxygen decreased respiratory rate and increased tidal volume and minute ventilation. Helium:oxygen decreased inspiratory time. Both gases increased total respiratory cycle time and decreased the inspiratory/total time ratio, the reduction in the latter being significantly greater with helium:oxygen. Peak inspiratory flow rate increased more with helium:oxygen. PaO2 increased with both gases, whereas PaCO2 decreased more with helium:oxygen (values shown are mean+/-SD) (52+/-6 torr [6.9+/-0.8 kPa] vs. 55+/-8 torr [7.3+/-1.1 kPa] and 48+/-6 torr [6.4+/-0.8 kPa] vs. 54+/-7 torr [7.2+/-0.9 kPa] for air:oxygen and helium:oxygen, respectively; p<.05). When hypercapnia was severe (PaCO2 >56 torr [7.5 kPa]), PaCO2 decreased by > or =7.5 torr (1 kPa) in six of seven patients with helium:oxygen and in four of seven patients with air:oxygen (p<.01). Dyspnea score (Borg scale) decreased more with helium:oxygen than with air:oxygen (3.7+/-1.6 vs. 4.5+/-1.4 and 2.8+/-1.6 vs. 4.6+/-1.5 for air:oxygen and helium:oxygen, respectively; p<.05). Mean arterial blood pressure decreased with air:oxygen (76+/-12 vs. 82+/-14 mm Hg; p<.05) but remained unchanged with helium:oxygen.
CONCLUSION: In decompensated COPD patients, noninvasive pressure support ventilation with helium:oxygen reduced dyspnea and PaCO2 more than air:oxygen, modified respiratory cycle times, and did not modify systemic blood pressure. These effects could prove beneficial in COPD patients with severe acute respiratory failure and might reduce the need for endotracheal intubation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579259     DOI: 10.1097/00003246-199911000-00017

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

Review 1.  Best evidence topic report. Use of Heliox in the management of acute exacerbation of COPD.

Authors:  Dhananjay Kumar; Rajesh Kumar Saksena
Journal:  Emerg Med J       Date:  2007-01       Impact factor: 2.740

2.  Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting.

Authors:  Sean P Keenan; Tasnim Sinuff; Karen E A Burns; John Muscedere; Jim Kutsogiannis; Sangeeta Mehta; Deborah J Cook; Najib Ayas; Neill K J Adhikari; Lori Hand; Damon C Scales; Rose Pagnotta; Lynda Lazosky; Graeme Rocker; Sandra Dial; Kevin Laupland; Kevin Sanders; Peter Dodek
Journal:  CMAJ       Date:  2011-02-14       Impact factor: 8.262

3.  Helium-oxygen decreases inspiratory effort and work of breathing during pressure support in intubated patients with chronic obstructive pulmonary disease.

Authors:  Didier Tassaux; Marc Gainnier; Anne Battisti; Philippe Jolliet
Journal:  Intensive Care Med       Date:  2005-09-20       Impact factor: 17.440

4.  Heliox in the treatment of chronic obstructive pulmonary disease.

Authors:  R Andrews; M Lynch
Journal:  Emerg Med J       Date:  2004-11       Impact factor: 2.740

5.  Comparative effects of helium-oxygen and external positive end-expiratory pressure on respiratory mechanics, gas exchange, and ventilation-perfusion relationships in mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Philippe Jolliet; Christine Watremez; Jean Roeseler; J C Ngengiyumva; Marc de Kock; Thierry Clerbaux; Didier Tassaux; Marc Reynaert; Bruno Detry; Giuseppe Liistro
Journal:  Intensive Care Med       Date:  2003-07-08       Impact factor: 17.440

Review 6.  Heliox for treatment of exacerbations of chronic obstructive pulmonary disease.

Authors:  G Rodrigo; C Pollack; C Rodrigo; B Rowe
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  Helium-oxygen reduces work of breathing in mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Marc Gainnier; Jean-Michel Arnal; Patrick Gerbeaux; Stéphane Donati; Laurent Papazian; Jean-Marie Sainty
Journal:  Intensive Care Med       Date:  2003-07-25       Impact factor: 17.440

8.  Effects of helium-oxygen on respiratory mechanics, gas exchange, and ventilation-perfusion relationships in a porcine model of stable methacholine-induced bronchospasm.

Authors:  Christine Watremez; Giuseppe Liistro; Marc deKock; Jean Roeseler; Thierry Clerbaux; Bruno Detry; Marc Reynaert; Pierre Gianello; Philippe Jolliet
Journal:  Intensive Care Med       Date:  2003-05-16       Impact factor: 17.440

Review 9.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Bench experiments comparing simulated inspiratory effort when breathing helium-oxygen mixtures to that during positive pressure support with air.

Authors:  Andrew R Martin; Ira M Katz; Katharina Jenöfi; Georges Caillibotte; Laurent Brochard; Joëlle Texereau
Journal:  BMC Pulm Med       Date:  2012-10-03       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.